Learn about Herceptin® (trastuzumab), a targeted therapy approved for HER2+ metastatic breast cancer treatment. See full safety & Boxed Warnings for more information.

Sep 17, 2025 · Trastuzumab is effective as a first treatment for HER2-positive metastatic breast cancer, as well as a treatment for metastatic breast cancer that has progressed on chemotherapy. Learn …

Trastuzumab (brand name: Herceptin) is a targeted therapy known as a monoclonal antibody, a modified version of an immune system protein, that can attach to proteins on HER2-positive breast …

Oct 22, 2025 · Herceptin (chemical name: trastuzumab) is a HER2 inhibitor targeted therapy. Herceptin works against HER2-positive breast cancers by blocking the ability of the cancer cells to receive …

Dec 14, 2025 · Breast cancer Gastric cancer Gastroesophageal junction cancer Because HER2 drives tumor aggressiveness, it represents an ideal target for precision therapy. Development, Brand Name, …

Apr 14, 2024 · Find out all you need to know about Herceptin (trastuzumab) for early and more advanced HER2-positive breast cancer, including what to expect, outcomes, side effects, and more.

6 days ago · On December 15, 2025, the U.S. Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (Enhertu®) in combination with pertuzumab for the first-line treatment …

6 days ago · The FDA approved trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive metastatic breast cancer after DESTINY-Breast09 showed major PFS gains.

Trastuzumab (Herceptin) is a targeted therapy for treating breast cancer. Find out when it's used, how it works and possible side effects.

6 days ago · The U.S. Food and Drug Administration has granted a breakthrough approval for a combination therapy designed to treat adults with unresectable or metastatic HER2-positive breast …